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S186 Oral Presentationsrespectively. In multivariate model, 1-year and long-term OS were
better in boys (p 5 0.024) and patients receiving a pre-cryo TNC
. 2.5x107/kg (p 5 0.0002). In patients with malignancies, higher
HLA-B mismatching (2 vs. 0 or 1) and in non-malignancy patients,
higher HLA-DRB1 mismatching (1 vs. 0) led to worse OS (table).
HLA-A mismatching (1 vs. 0) had no impact. OS in minority and
Caucasian patients were similar. Probability of malignancy relapse
at 5 yrs was 10.1%(95%CI 5.8%-14.4%).
Table 1. Overall Survival: Significant Factors in Multivariate
Analysis
All patients Hazard Ratio (95% CI) p - valuePre-Cryo TNC < or 5 2.5x10e7/kg 1.000
Pre-Cryo TNC > 2.5x10e7/kg 0.415 (0.26-0.66) 0.0002
Recipient Sex: Male 1.000
Recipient Sex: Female 1.431 (1.05-1.95) 0.0241
Malignant Diagnoses
Recipient CMV Negative 1.000
Recipient CMV Positive 1.482 (1.02-2.16) 0.04
0 or 1 HLA-B Mismatch 1.000
2 HLA-B Mismatches 2.832 (1.24-6.49) 0.0139
Non-Malignant Diagnoses
Pre-Cryo TNC < or 5 8.6x10e7/kg 1.000
Pre-Cryo TNC > 8.6x10e7/kg 0.570 (0.34-0.96) 0.0354
No HLA-DRB1 Mismatch 1.000
1 HLA-DRB1 Mismatch 1.732 (1.02-2.93) 0.0412CONCLUSIONS: 4/6 matched UCBT is effective and carries low
probabilities of graft failure, acute GVHD (III-IV) and chronic
GVHD in children and young patients. These outcomes are similar
to those reported with better matched UCB grafts and support the
use of 4/6 UCBT for patients lacking other donors. HLA-A, -B
and -DRB1 mismatching has differential outcome on OS. Further
studies will help in utilizing these differences to optimize CBU
selection.88
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Background:CAYA with ALL or AML in third complete remission
(CR3), refractory relapse (RR) or induction failure (IF) continue to
have extremely poor prognosis,\ 20% EFS (Gaynon, BJH, 2005,
Wells et al, JCO, 2003). CLO is an inhibitor of DNA polymerase
and ribonucleotide reductase and has demonstrated activity in
CAYAwith relapsed ALL/AML (Jeha et al., JCO, 2006, 2009). Stud-
ies suggest synergy with cytarabine (Faderl et al, Blood, 2005). CLO
with cytarabine has shown greater rates of CR than CLO alone in
adults with AML and in CAYA with relapsed ALL/ AML (Faderl
et al, Blood, 2006, 2008; Cooper et al, ASH, 2009).We sought to de-
termine maximum tolerated dose (MTD) or tolerable dose of CLO
and assess the safety, progression-free survival (PFS) and overall sur-
vival (OS) of CLO, cytarabine and TBI followed by AlloSCT in
CAYA with poor-risk ALL/ AML.
Methods: This is a multi-center phase I/II trial of novel condition-
ing regimen of CLO (dose escalation: 40mg/m2 [n 5 3], 46 mg/m2
[n 5 3], 52 mg/m2 [n 5 8]) x5d, sequential (4 hrs later) cytarabine
1000 mg/m2 x6d and TBI (1200cGy) followed by AlloSCT from
matched related or unrelated donors in CAYA with ALL/AML in
CR3, RR or IF. Pts with unrelated grafts received R-ATG.GVHDprophylaxis consisted of tacrolimus andMMF (Bhatia/Cairo
et al., BBMT, 2009). Kaplan-Meier method was used to determine
the probabilities of engraftment, GVHD, PFS and OS.
Results: 14 pts, median age: 10.6 yrs (5-18); M:F: 10:4, ALL/AML:
11:3 (9 CR3, 2 RR, 3 IF), 6 related donors, 8 unrelated donors (5
BM/PBSCs, 3 UCB). Median TNC and CD34 dose was 5.04x108/
kg and 5.04x106/kg for BM/PBSCs and 4.0x107/kg and 1.8x105/
kg for UCB. Probabilities of neutrophil and platelet engraftment
and grade II-IV aGVHD were 100%, 91.7% and 51.8%, respec-
tively. All achieved 100% whole blood donor chimerism by day 30.
Day 100 TRM was 0%. CLO dose was tolerable at 52mg/m2/
d x5d and is being used in the phase II setting. No serious adverse
events related to CLO were observed. 2 pts experienced progressive
disease at days 90 and 126. 10 pts are alive in continuous CR at me-
dian 171 days (42-834). Probabilities of 1-yr PFS and OS are 60.2%
(CI95: 24-83%) and 54.0% (CI95: 18-80%), respectively.
Conclusions: Preliminary results suggest this regimen followed by
AlloSCT is safe and well tolerated in CAYA with poor-risk ALL/
AML with CLO dose of 52 mg/m2. Very early results are encourag-
ing with respect to low risk of early leukemic relapse with this
conditioning regimen.89
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Background:We analyzed the outcome of 18 consecutive-children
who receivedmatched unrelated donor (MUD) haematopoietic stem
cell transplantation (HCT) for idiopathic severe aplastic anaemia
(SAA) using an Alemtuzumab non-total body irradiation (TBI) based
conditioning regime.
Design and Methods: We conducted a multicentre retrospective
analysis to determine the efficacy of non-TBI, Alemtuzumab-based
conditioning regimens for HCT in idiopathic SAA. The outcomes
analysed were event free survival (EFS), overall survival (OS),
graft-versus-host-disease (GVHD) and viral reactivations.
Results: The median age transplantation was 14.3 years (range 0.7-
19 years). Fourteen of the 18 patients had failed to respond to prior
immunosuppressive therapy. Analysis of 18 patients who received 10
antigen (HLA-A,-B,-C,-DRB1,-DQB1) MUD HCT for idiopathic
SAA between 1999 and 2007 showed an EFS and OS of 100% at
a median follow-up of 3.7 years (range 2.5-10.83 years). Nine of
the 18 patients were full donor chimerae and the other 9 were stable
mixed chimerae (median donor chimerism 100 %; range 95-100 %).
All patients have normal neutrophil and platelets counts and are
transfusion independent. There were no cases of severe acute or ex-
tensive chronic GVHD. Eleven patients remained free of acute
GVHD, 6 developed grade I and only a single patient developed
grade II GVHD (cumulative incidence of grade I-II GVHD 38.8
%). No patient developed grade III-IV acute GVHD. Two patients
developed limited chronic GVHD of the skin (cumulative incidence
of limited chronic GVHD 11.1 %) and no patients developed exten-
sive chronic GVHD.There was a low rate of viral/bacterial morbid-
ity requiring treatment (adenoviral reactivation responding to
cidofovir [1], CMV reactivation responding to donor lymphocyte
infusion [1] and MRSA abscess[1]). There were no cases of EBV
post-transplant lymphoproliferative disease .
Conclusion: These data suggest that Alemtuzumab is sufficiently
immunosuppressive to permit engraftment following MUD HCT
in SAA whilst minimising toxicity and avoiding serious GVHD.
This approach avoids the potential concerns of late carcinogenesis
which accompany the use of TBI in this disease. In the absence of
a matched sibling donor, our data suggests that MUD HCT could
be considered as first line therapy before immune suppression for
